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Abstract 
Although alcohol intake is an established risk factor for overall breast cancer, few studies have looked at the relation‑
ship between alcohol use and breast cancer risk by the four major subtypes of breast cancer and very few data exist 
in the alcohol‑breast cancer relationship in Spanish women. A population‑based case‑control study was conducted 
in Galicia, Spain. A total of 1766 women diagnosed with invasive breast cancer between 1997 and 2014 and 833 
controls participated in the study. Data on demographics, breast cancer risk factors, and clinico‑pathological char‑
acteristics were collected. We examined the alcohol‑breast cancer association according to the major breast cancer 
subtypes [hormone‑receptor‑positive, HER2‑negative (luminal A); hormone‑receptor‑positive, HER2‑positive (lumi‑
nal B); hormone‑receptor‑negative, HER2‑negative (TNBC); and hormone‑receptor‑negative, HER2‑positive (HER2 
overexpressing)] as well as grade and morphology in Spanish women. With the exception of HER2 overexpressing, the 
risk of all subtypes of breast cancer significantly increased with increasing alcohol intake. The association was similar 
for hormonal receptor positive breast cancer, i.e., luminal A and luminal B breast cancer (odds ratio, OR 2.16, 95 % 
confidence interval, CI 1.55–3.02; and OR 1.98, 95 % CI 1.11–3.53, respectively), and for TNBC (TNBC: OR 1.93, 95 % CI 
1.07–3.47). The alcohol‑breast cancer association was slightly more pronounced among lobular breast cancer (OR 
2.76, 95 % CI 1.62–4.69) than among ductal type breast cancers (OR 2.21, 95 % CI 1.61–3.03). In addition, significant 
associations were shown for all grades, I, II and III breast cancer (OR 1.98, 95 % CI 1.26–3.10; OR 2.34, 95 % CI 1.66–3.31; 
and OR 2.16, 95 % CI 1.44–3.25 for Grades I, II and III, respectively). To our knowledge, this is the first study to examine 
the association of breast cancer subtypes and alcohol intake in Spanish women. Our findings indicate that breast 
cancer risk increased with increasing alcohol intakes for three out of the four major subtypes of breast cancer. The 
association was similar for hormonal receptor positive breast cancer, i.e., luminal A and luminal B breast cancer, and for 
TNBC. The association seemed to be slightly more pronounced for lobular than ductal breast cancers. No differences 
were detected by grade.
© 2016 Gago‑Dominguez et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International 
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any 
medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made.
Background
Alcohol was first suggested to increase the risk of breast 
cancer in the early 1980s by several case-control stud-
ies conducted in North America (Rosenberg et al. 1982). 
After this first observation, more than 100 epidemiologi-
cal studies have been published, and the alcohol-induced 
breast cancer risk is now established. In its monographs 
on alcohol consumption, the International Agency for 
Research on Cancer (IARC) has concluded that alco-
hol consumption is an established cause of breast can-
cer (IARC 2012). However, despite this abundant body 
of evidence, risk differences according to the four major 
subtypes of breast cancer are still unknown (luminal A, 
luminal B, TNBC and HER2 overexpressing).
Numerous epidemiological studies have showed that 
alcohol use is more strongly associated with risk of 
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estrogen receptor [ER] + than ER– breast cancer. A meta-
analysis including 20 epidemiological studies (4 cohort and 
16 case-control studies) (Suzuki et  al. 2008), reported an 
increased risk of 27 % for ER+ and of 14 % for ER− breast 
cancers comparing the highest vs. the lowest consump-
tion categories of alcohol drinking. However, very few data 
exist on risk of the four major breast cancer subtypes fur-
ther defined by HER2 status. There is also lack of data on 
the alcohol-breast cancer relationship in Spanish women.
The alcohol-breast cancer association is particularly inter-
esting to study in the Spanish population. According to 
the Asociación Española Contra el Cáncer (AECC, Spanish 
Cancer Society), there are 26,000 new breast cancer cases 
per year in Spain, which is 30 % of all cancer cases in women, 
but there is a significant variability by region. Thus, in Cata-
lonia the incidence rate is 83.9 cases per 100,000 while the 
national incidence rate is just 50.9 cases per 100,000 (Aso-
ciación Española Contra el Cáncer, AECC 2014).
Alcohol use is deeply rooted in Galician culture, and 
its abuse constitutes an important public health prob-
lem. The per capita annual rate of alcohol consumption 
in Galicia is 40 % higher than the national average. The 
traditional rural model of drinking in which alcohol is 
perceived as a daily nourishment still predominates. 
However, an urban consumer model is quickly growing, 
especially among young women (Mateos et al. 2002).
Clinically, breast cancer represents a heterogeneous 
disease that is mainly grouped based on its hormone 
receptor (estrogen receptor [ER] or progesterone recep-
tor [PR] positivity) and amplification of the ERBB2 gene 
(hereafter referred to as HER2+) (Sorlie 2004). Genomic 
profiling has identified at least two major groups (luminal 
and basaloid) primarily based on their hormone recep-
tor status (Perou et al. 2000; Sorlie et al. 2001). These two 
major groups differ by age, race/ethnicity, reproductive 
patterns, lifestyle factors, stage at diagnosis, and survival 
(Carey et al. 2006; Millikan et al. 2008; Parise et al. 2009; 
Trivers et  al. 2009). Epidemiological studies also sup-
port these differences (Martinez et al. 2010). Thus, many 
breast cancer factors such as age at onset, menopausal 
status (Clavel-Chapelon 2002; Althuis et  al. 2004), and 
timing and number of births (Pathak et al. 2000; Palmer 
et  al. 2003), affect the risk of breast cancer in an oppo-
site direction (increasing or decreasing risk) depending 
on its hormonal receptor status (Anderson et  al. 2014). 
Similarly, breast cancer risks from genetic variants that 
have recently been identified in genome-wide association 
studies, also clearly differ by hormonal receptor status, 
as there are specific genetic variants associated only with 
ER+ breast cancers and other with TNBC (Michailidou 
et al. 2013; Garcia-Closas et al. 2013).
Using data from the Breast Oncology Galician Network 
(BREOGAN) study, we examined the alcohol-breast 
cancer association according to the major breast cancer 
subtypes as well as grade and morphology in Spanish 
women.
Results
Table  1 shows characteristics of the cases (n  =  1766) 
and controls (n = 833). Fifteen percent of cases vs. 8.6 % 
of controls reported to have a family history of breast or 
ovarian cancer, and 39.5 % of cases vs. 47.9 % of controls 
reported having used oral contraceptives. Cases were 
similar to controls on all other factors including body 
mass index (BMI), use of hormone replacement therapy 
(HRT), and reproductive or other hormonal characteris-
tics. With regards to alcohol consumption, 46.1 % of cases 
were abstainers, 37.3 % consumed 1–7 drinks/week (light/
moderate drinkers), and 16.6 % consumed >7 drinks/week 
(heavy drinkers). The corresponding figures among con-
trols were 50.4, 38.5, and 11.1 %, respectively. Consistent 
with the literature, invasive ductal carcinoma was the most 
common histological type (85.2  %), and the distribution 
of the four major breast cancer subtypes were 67.3, 12.6, 
14.4, and 5.7 %, for luminal A, luminal B, TNBC and HER2 
overexpressed, respectively. Mean tumor size was 2.4 cm.
The risk of breast cancer significantly increased with 
increasing alcohol intake Compared to abstainers, 
the ORs for light/moderate and heavy drinking were 
1.05 (95  % CI 0.86–1.28) and 2.19 (95  % CI 1.61–2.98) 
(P < 0.001), respectively.
Table 2 presents ORs for the association between alco-
hol consumption and tumor subtypes. With the excep-
tion of HER2 overexpressing, the risk of all subtypes of 
breast cancer significantly increased with increasing alco-
hol intake. Comparing heavy drinkers to abstainers, the 
association was similar for hormonal receptor positive 
breast cancer (luminal A, OR 2.16, 95  % CI 1.55–3.02; 
luminal B, OR 1.98, 95 % CI 1.11–3.53), and TNBC (OR 
1.93, 95 % CI 1.07–3.47).
When we categorized breast cancers by HER2 postive 
or negative tumors regardless of hormonal receptor sta-
tus, a slightly stronger association was shown for HER2 
negative (OR for the highest category of alcohol drink-
ing =2.12, 95 % CI 1.53–2.94) than HER2 positive breast 
cancer (OR 1.77, 95 % CI 1.08–2.92) (Table 3).
Table  4 presents the risk of alcohol intake and breast 
cancer by grade and morphology. The alcohol-breast 
cancer association was present among all breast cancer 
grades, I–III (OR 1.98, 95 % CI 1.26–3.10; OR 2.34, 95 % 
CI 1.66–3.31; and OR 2.16, 95 % CI 1.44–3.25 for Grades 
I, II, and III, respectively). Likewise, a positive association 
was shown for alcohol consumption and both histologi-
cal types, with only a slightly more pronounced risk for 
lobular (OR 2.76, 95 % CI 1.62–4.69) than ductal breast 
cancers (OR 2.21, 95 % CI 1.61–3.03).
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We also examined the alcohol-breast cancer relation-
ship stratified by family history of breast cancer. No dif-
ferences were found (ORs of breast cancer associated 
with heavy drinking among cases with a positive family 
history of breast cancer was 1.73 (95 % CI 1.07–2.81), and 
1.88 (95  % CI 1.39–2.53) among those without a family 
history of cancer).
Discussion
Our findings indicate that, with the exception of HER2 
overexpressing tumors, for which we lacked precision, 
the risk of all subtypes of breast cancer increased with 
increasing alcohol, as measured by average weekly intake; 
the risk seemed to be similar for hormonal receptor posi-
tive breast cancers, i.e., luminal A and luminal B sub-
types, and for TNBC. Our findings are consistent with 
those of previous studies, which found alcohol consump-
tion to be primarily associated with an increased risk of 
hormone receptor-positive breast cancer, primarily ER+ 
breast cancer (Lew et al. 2009; Li et al. 2010; Chen et al. 
2011), although there was also an increased risk for ER− 
breast cancer. A meta-analysis of 20 studies reported an 
increased risk of 27 % of all ER+ and of 14 % of all ER-
breast cancers for the highest vs. the lowest consump-
tion categories of alcohol drinking (Suzuki et  al. 2008). 
However, majority of previous studies centered on study-
ing the effect of alcohol in ER+ breast cancer versus ER− 
breast cancer because they lacked information on HER2 
receptor, which precluded them from examining more 
specific breast cancer subtypes further defined by HER2 
receptor. Because we had this information, we were able 
to examine the four major cancer subtypes, i.e., luminal 
A, luminal B, TNBC, and HER2-overexpressing breast 
cancer. Thus, among the group formerly categorized as 
hormonal receptor positive breast cancer (majority ER+ 
breast cancer), we found increased risk for both lumi-
nal A (ER+, PR+, HER2−) and luminal B (ER+, PR+, 
HER2+) breast cancers. Among the group categorized as 
hormonal receptor negative breast cancer (majority ER− 
breast cancers), we found increased risk for TNBC (ER−, 
PR−, HER2−), a finding consistent with a few studies 
that previously examined the TNBC subtype (Dolle et al. 
Table 1 Characteristics of breast cancer patients and con-





Age, year 56.3 ± 12.3 53.2 ± 13.2
Age at menarche, year 13.2 ± 1.8 13.0 ± 1.7
Menopausal status
 Postmenopausal 1088 (65.0) 473 (58.0)
 Premenopausal 587 (35.0) 342 (42.0)
Family historya
 No 1459 (84.9) 735 (91.4)
 Yes 259 (15.1) 69 (8.6)
 Age at firts full‑term pregnancy, year 24.8 ± 4.9 24.6 ± 5.2
Parity
 No 307 (17.5) 86 (10.5)
 Yes 1443 (82.5) 730 (89.5)
 Number of pregnancies 2.0 ± 1.4 1.9 ± 1.2
Breastfeeding
 No 782 (46.5) 340 (41.7)
 Yes 900 (53.5) 475 (58.3)
 Lifetime breastfeeding, months 6.0 ± 10.8 6.6 ± 11.0
 Body mass index, kg/m2 25.7 ± 4.5 26.6 ± 4.8
Oral contraceptive use
 Never 994 (60.5) 424 (52.1)
 Ever 649 (39.5) 390 (47.9)
Alcohol frequency
 0 drinks/week 752 [46.1] 417 [50.4]
 1–7 drinks/week 607 [37.3] 319 [38.5]
 >7 drinks/week 270 [16.6] 92 [11.1]
Smoking status
 No 1124 [68.2] 542 [65.2]
 Ex‑smoker 268 [16.3] 147 [17.7]
 Current smoker 256 [15.5] 142 [17.1]
Hormone replacement therapy
 Never 1456 (90.3) 719 (91.1)
 Ever 156 (9.7) 70 (8.9)
Grade
 I 353 (22.3)
 II 808 (51.1)
 III 421 (26.6)
Histology type
 Ductal invasive 1493 (85.2)
 Lobular invasive 164 (9.4)
 Other 95 (5.4)
Tumor size (2.4 ± 1.6) cm
ER
 Positive 1321 (79.3)
 Negative 345 (20.7)
PR
 Positive 1093 (66.2)
 Negative 559 (33.8)







 ER+/or PR+/HER2− 952 (67.3)
 ER+/or PR+/HER2+ 178 (12.6)
 ER−/PR−/HER2− 204 (14.4)
 ER−/PR−/HER2+ 80 (5.7)
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2009; Trivers et  al. 2009), although one prior study did 
not find this effect (Kabat et  al. 2011), but did not find 
increased risk for HER2− overexpressing breast cancer 
(ER−, PR−, HER2+).
When we categorized breast cancer by HER2 expres-
sion regardless of hormonal receptor status, our study 
showed that alcohol may be more strongly associated 
with the risk of HER2− than HER2+ breast cancer, 
although very slightly so. The followings lines of evidence 
support this observation. In a study by Nichols et  al. 
(2005), alcohol significantly increased the risk of breast 
cancer in HER2− breast cancer but not in HER2+ cases. 
Similarly, in a case-case design by Kwan et  al. (2009), 
women diagnosed with luminal A (ER+, PR+, HER2−) 
breast cancers were more likely to drink alcohol com-
pared to women diagnosed with luminal B breast cancers 
(ER+, PR+, HER2+).
Experimental data suggest that alcohol consump-
tion promotes HER2 mammary tumor development in 
MMTV-neu mice only in the presence of ovarian hor-
mones. In that study, alcohol consumption increased risk 
of HER2 positive breast cancer in non-ovariectomized 
mice but not in ovariectomized mice. Therefore, it is fea-
sible that alcohol may affect HER2 tumor development 
only in the presence of normal circulating estrogen lev-
els via the estrogen-signaling pathway (Wong et al. 2012). 
However, in our study we lacked precision on our esti-
mates on HER2 overexpressed breast cancers to be able 
Table 2 Associations between alcohol consumption and breast cancer by tumor subtype
a Polytomous regression analysis. Adjusted for age at diagnosis, age at menarche, parity, breastfeeding, oral contraceptive use, menopausal status, BMI, smoking 
status, and family history
b Study subjects who consumed 1–7 drinks/week were considered light/moderate drinkers, and those who consumed >7drinks/week were considered heavy drinkers
Alcohol intake Controls Luminal A Luminal B TNBC HER2 overexpressing
N N ORa (95 % CI) N ORa (95 % CI) N ORa (95 % CI) N ORa (95 % CI)
Abstainers 389 359 1.0 59 1.0 62 1.0 31 1.0
Light/Moderate drinkers 
(1–7 drinks/week)
293 291 1.03 (0.82, 1.28) 62 1.37 (0.92, 2.03) 50 1.05 (0.70, 1.58) 19 0.78 (0.43, 1.41)
Heavy drinkersb (>7drinks/
week)
65 141 2.16 (1.55, 3.02) 
P < 0.001
20 1.98 (1.11, 3.53) 
P = 0.019
19 1.93 (1.07, 3.47) 
P = 0.091
9 1.51 (0.68, 3.36)  
P = 0.730
Table 3 Associations between alcohol consumption and breast cancer by HER2 status
a Polytomous regression analysis. Adjusted for age at diagnosis, age at menarche, parity, breastfeeding, oral contraceptive use, menopausal status, BMI, smoking 
status, and family history
b Study subjects who consumed 1 to 7 drinks/week were considered light/moderate drinkers, and those who consumed > 7drinks/week were considered heavy 
drinkers
Alcohol intake Controls HER2 negative  N ORa (95 % CI) HER2 positive N ORa (95 % CI)
Abstainers 389 421 1.0 92 1.0
Light/Moderate drinkers (1–7 drinks/week) 293 343 1.03 (0.83, 1.28) 81 1.13 (0.81, 1.59)
Heavy drinkersb (>7 drinks/week) 65 160 2.12 (1.53, 2.94) P < 0.001 29 1.77 (1.08, 2.92) P = 0.052
Table 4 Associations between alcohol consumption and breast cancer by grade and tumor histology
a Polytomous regression analysis. Adjusted for age at diagnosis, age at menarche, parity, breastfeeding, oral contraceptive use, menopausal status, BMI, smoking 
status, and family history
b Study subjects who consumed 1–7 drinks/week were considered light/moderate drinkers, and those who consumed >7drinks/week were considered heavy drinkers
Alcohol intake Controls GRADE HISTOLOGY
Grade I Grade II Grade III Ductal Lobular
N Cases ORa (95 %CI) Cases ORa (95 % CI) Cases ORa (95 % CI) Cases ORa (95 % CI) Cases ORa (95 % CI)
Abstainers 389 112 1.0 290 1.0 159 1.0 535 1.0 57 1.0
Light/Moderate drinkers 293 109 1.22 (0.90, 1.67) 225 0.99 (0.78, 1.25) 130 1.06 (0.80,1.40) 436 1.05 (0.86, 1.29) 49 1.04 (0.69, 1.59)
Heavy drinkersb 65 41 1.98 (1.26, 3.10) 120 2.34 (1.66, 3.31) 58 2.16 (1.44, 3.25) 205 2.21 (1.61, 3.03) 29 2.76 (1.62, 4.69)
P = 0.007  P < 0.001 P = 0.003  P < 0.001  P = 0.003
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to detect if such a hormonal receptor-dependent differ-
ence exists in the alcohol—HER2+/breast cancer rela-
tionship. Also, our limited sample size precluded us from 
conducting analyses stratified by oophorectomy; how-
ever, no differences were shown when we examined the 
association stratified by menopausal status.
Consistent with previous case-control and cohort stud-
ies (Li et al. 2003a, 2006, 2010), our results show that the 
alcohol-breast cancer association appeared to be slightly 
more pronounced among lobular breast cancers than 
among ductal type breast cancers. It is important to note 
that ductal cancer is much more common than lobu-
lar cancer accounting for about 70 percent of all breast 
cancers whereas lobular cancer accounts for only about 
10–15 percent of cases. It is not clear why alcohol affects 
the risk of lobular and ductal breast cancer differently. 
However, this finding is especially interesting in light 
of results from other studies demonstrating that use of 
combined estrogen and progestin hormone replacement 
therapy, another established risk factor for breast cancer, 
is also more strongly related to risk of lobular than ductal 
breast cancer (Li et  al. 2000; 2003b; Chen et  al. 2002; 
Newcomb et  al. 2002; Newcomer et  al. 2003). The data 
seem to suggest that alcohol use may be another hor-
monally related risk factor for breast cancer that exerts 
a stronger effect on risk of lobular than ductal breast can-
cer, as pointed out by Li et al.  (2003a). The alcohol-breast 
cancer association was present across all three breast 
cancer grades. There are very sparse data on the alcohol-
breast cancer relationship by grade. In a previous study, 
the effect of alcohol consumption on breast cancer sur-
vival was not affected by grade (Reding et al. 2008).
There are several carcinogenic mechanisms of alco-
hol. The mechanism receiving most attention in the 
epidemiological literature is the increase in estrogen 
levels (Singletary and Gapstur 2001; Chen et  al. 2011). 
Indeed, hormones play an important role in alcohol-
related breast cancer development. Ethanol stimulates 
both cell proliferation and the transcriptional activity of 
liganded ER, which in turn increases levels of circulat-
ing estrogens that control proliferation and morphogen-
esis in the breast (Rehm 2014; Singletary and Gapstur 
2001; Chen et al. 2011). However, in an important study, 
Dorgan et  al. (1994) showed that consumption of 15  g 
of alcohol per day did not affect estrogen levels in post-
menopausal women, and the alcohol-induced estrogen 
hypothesis was also not confirmed by subsequent studies 
(Allen et al. 2009; Li et al. 2010; Key et al. 2011). There-
fore, the evidence suggests that increased estrogen levels 
are not the only mechanism whereby daily alcohol con-
sumption increases breast cancer risk in postmenopausal 
women. A second hypothesis is that alcohol is a cumula-
tive breast carcinogen, suggesting that chronic exposure 
to alcohol over the years is the mechanism responsible 
for its increased risk of breast cancer. In a recent review, 
Brooks and Zakhari concluded that results from epide-
miologic studies were mostly consistent with the cumu-
lative carcinogen hypothesis (Brooks and Zakhari 2013).
Many epidemiologic studies have confirmed a relation-
ship between alcohol consumption and breast cancer risk 
in women. Still, important questions remain about the 
mechanistic pathway of this relationship, which impact 
the interpretation of the epidemiologic results and their 
implications for disease prevention and women’s health. 
We have previously proposed a novel mechanism for 
alcohol carcinogenic effect in the breast breast (Gago-
Dominguez et  al. 2006). Specifically, we proposed that 
alcohol´s antioxidant and anti-apoptotic effect could be 
one of the mechanisms responsible for its carcinogenic 
effect (Teixeira et  al. 1995; Chajes et  al. 1996; Gago-
Dominguez et  al. 2006). In the present paper, we found 
alcohol to be slightly more strongly associated with the 
risk of HER2− breast cancer. Some experimental find-
ings suggest that the HER2 oncogene behaves as antioxi-
dant and anti-apoptotic. Menendez et al. (2005) showed 
that γ-linolenic acid (GLA) inhibits the expression of the 
HER2 oncogene in cancer cell lines in vitro and that con-
current administration of GLA and trastuzumab, which 
is an anti–HER2 antibody, to HER2− overexpressing 
breast cancer cells caused significant, synergic increases 
in apoptosis and reductions in cancer growth formation 
(Das 1999; Simeone et al. 2003, 2004).
Although several regional and national agencies han-
dling matters concerning preventive alcohol policies have 
been established in Spain since the 1980s, there is still a 
weak formal control on alcohol related issues (European 
Commission; Social-and health-related research and 
Development Centre 2002). Binge drinking, particularly 
among youth on weekend nights, has become a health 
and social issue in Spain which has important negative 
effects involving also non-drinkers. Regarding alcohol 
consumption in women, in the recent ESTUDE survey 
1994–2010 (ESTUDES 2010), the prevalence of alcohol 
consumption in students 14–18  years of age has been 
shown to be slightly higher in women than men for all 
three time indicators under study (any time in life, in the 
last 12 months, in the last 30 days).
Although we did not collect information on binge 
drinking or heavy drinking in early life in our study, the 
age at exposure may have modulated breast cancer risk 
in later life. Since binge drinking is a recent phenom-
enom in Spain, originating in the last 5–10  years, there 
might have not elapsed sufficient latency period to study 
this exporure on breast cancer risk in the present study. 
Results from a cross-sectional study (Galán et  al. 2014) 
indicate that prevalence of heavy drinkers and binge 
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drinkers in Spanish women during the last year was 0.7 
and 7 %, respectively. However, this is an important expo-
sure that needs to be taken into account in future studies 
on the alcohol-breast cancer relationship.
Results of this study must be interpreted in light of 
its limitations. First, we could not examine the alcohol-
breast cancer relationship by type of alcoholic beverages 
such as wine, beer and spirits since we did not have infor-
mation on beverage types. Also, measurement of alcohol 
intake can be difficult and misclassification of this vari-
able can occur. Another limitations are the retrospective 
nature of the study. However, any misreporting of alcohol 
consumption is unlikely to be influenced by tumor sub-
type. Conversely, an important strength of our study is 
the available information on HER2 in addition to hormo-
nal receptor status.
In the first investigation, to our knowledge, of the effect 
of alcohol consumption on breast cancer in Spanish 
women, we found that breast cancer risk increased with 
increasing alcohol intakes for three out of the four major 
subtypes of breast cancer. The association was present 
for all grade I–III breast cancers and it was slightly more 
pronounced for lobular than ductal breast cancers.
Conclusion
To our knowledge, this is the first study to examine the 
association of breast cancer subtypes and alcohol intake 
in Spanish women. Our findings indicate that breast 
cancer risk increased with increasing alcohol intakes for 
three out of the four major subtypes of breast cancer. The 
association appeared to be similar for hormonal recep-
tor positive breast cancer, i.e., luminal A and luminal B 
breast cancer, and for TNBC. The association seemed 
to be slightly more pronounced for lobular than ductal 
breast cancers. No differences were detected by grade.
Methods
Study population
The BREast Oncology GAlician Network (BREOGAN) 
includes a population-based case-control study con-
ducted in the cities of Vigo and Santiago de Compostela, 
Spain, within a geographically defined health region 
that covers approximately one million inhabitants. Data 
collection methods have been previously described 
(Redondo et al. 2012; Ali et al. 2014; Rudolph et al. 2014). 
Cases comprised 1766 women with invasive breast can-
cer diagnosed and treated between 1997 and 2014 that 
were recruited at the Clinical University Hospitals of 
Santiago (CHUS) and Vigo (CHUVI).Controls were 
833 women living in the same population health area as 
cases free of cancer, except non-melanoma skin cancer. 
Response rates were 98 and 99 % for cases and controls, 
respectively. Ethics approval for this study was obtained 
from the Galician Ethics and Research Committee 
(CEIC, Comité Ético de Investigación Clínica de Galicia), 
responsible for the oversight of both university hospi-
tals CHUS and CHUVI from where all participants were 
recruited. All participants provided written informed 
consent. The study was conducted in accordance to the 
Helsinki Principles of 1975, as revised in 1983.
Data collection
Risk factor data
Risk factor information was collected through a risk fac-
tor questionnaire adapted from the Ella Binational Breast 
Cancer Study (Martinez et  al. 2013, 2010; Cruz et  al. 
2012) to meet the needs of the population in Spain. Clini-
cal and histopathological information was abstracted 
from computerized medical records by trained physi-
cians. The following variables were recorded: level of 
education [uneducated (less than primary education), 
primary education, secondary education, vocational 
training, 3 years degree (certificate, middle engineering), 
5 years degree (graduate school, bachelor´s degree, supe-
rior engineering), and PhD (doctorate)], lifetime breast-
feeding, age at menarche, age at first full-term pregnancy, 
parity (categorized as never vs. ever pregnant), age at 
diagnosis, age at menopause, menopausal status at diag-
nosis (categorized as pre and postmenopausal), num-
ber of pregnancies, oral contraceptive use (never, ever), 
body mass index (BMI), smoking status (never smoker, 
ex-smoker, current smoker) family history (categorized 
as none vs. one or more first degree relatives with breast 
and/or ovarian cancer). Alcohol consumption was evalu-
ated by the number of alcoholic drinks consumed regu-
larly per week in last year before reference date. Women 
with habitual alcohol consumption of 1–7 drinks/week 
were considered light/moderate drinkers, and those 
with alcohol consumption of  >7 drinks/week were con-
sidered heavy drinkers. The remainder, alcohol abstain-
ers or very occasional alcohol drinkers, were included 
in the same group. The alcohol categories correspond to 
the CDC definition of light/moderate and heavy drink-
ing among women (http://www.cdc.gov/alcohol/faqs.
htm#heavyDrinking).
Clinico‑pathological data
Histopathological information was abstracted from com-
puterized medical records by trained physicians. Immu-
nohistochemistry (IHC) analyses on paraffin-embedded 
material have been previously performed following 
standard procedures in Galician hospitals to determine 
the status of ER and PR. In every tumor, 4 μm histologi-
cal sections were cut and stained with hematoxylin and 
eosin for histopathological examination according to 
the criteria of the World Health Organization (Ellis et al. 
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2003). Histological grading was evaluated using the Not-
tingham modification of the Bloom-Richardson system 
(Frierson et  al. 1995). IHC analysis on paraffin-embed-
ded material was performed using a universal second 
antibody kit that used a peroxidase-conjugated labeled-
dextran polymer (EnVision®, Peroxidase/DAB; Dako, 
Glostrup, Denmark), with antibodies for ER (clone 6F11, 
dilution 1:50, water bath; Novocastra, Newcastle-upon-
Tyne, UK), PR (clone PgR 636, dilution 1:50, water bath; 
Dako, Glostrup, Denmark). Negative and positive con-
trols were concurrently run for all antibodies with sat-
isfactory results. Cells were considered immunopositive 
when diffuse or dot-like nuclear staining was observed 
regardless of the intensity of the staining; only nuclear 
immunoreactivity was considered specific. The number 
of positive cells was counted by two different observers 
independently. Whenever necessary, a consensus was 
reached using a double-headed microscope. ER and PR 
were considered positive when the percent of immu-
nostained nuclei was ≥10 %.
Immunohistochemistry (IHC) analyses were per-
formed to determine HER2 status (Dako). No immu-
nostaining (0) or weak membrane immunostaining (1+) 
was considered low HER2 expression (HER2). Strong 
membrane immunostaining (3+) was considered HER2 
overexpression (HER2+). Moderate membrane staining 
(2+) samples were further analyzed using fluorescence 
in  situ hybridization techniques; they were considered 
to be HER2+ if the ratio of cerb-B2/centromere 17 copy 
number was >2.0.
ER, PR and HER2 status (categorized as positive 
and negative), grade (categorized as I—well differenti-
ated–, II—moderately differentiated– and III—poorly 
differentiated or undifferentiated), histology type (cat-
egorized as invasive ductal carcinoma, invasive lobu-
lar carcinoma and other), and tumor size (mm). Of 
the 1766 women who participated in the study, 100 
had unknown ER status, 114 had unknown PR sta-
tus, and 340 had unknown HER2 status. One hun-
dred and eighty four women had unknown grade, 14 
had unknown histological type and 144 had unknown 
tumor size. Sixty-two women had unknown age at 
menarche, and 48, out of 1443 parous women, had 
unknown lifetime breastfeeding.
Statistical analyses
The association of breast cancer with alcohol con-
sumption was measured by odds ratios (ORs) and 
corresponding 95 % confidence intervals (CIs) using pol-
ytomous logistic regression. Analyses were adjusted for 
the following established risk or protective factors for 
breast cancer: age, age at menarche, parity, menopausal 
status, body mass index (BMI), smoking, breastfeeding, 
oral contraceptive use, and family history of first degree 
relatives with breast and/or ovarian cancer. Despite 
being an established breast cancer risk factor, we did 
not include use of hormone replacement therapy in 
the model because it was not significantly associated 
with breast cancer in the present study and very few 
people use this therapy in Spain (<10  % in the present 
study). Outcome (dependent) variables were breast can-
cer subtypes defined by ER, PR, and HER2 status (we 
defined four tumor subtypes (ER+/HER2− or PR+/
HER2− [luminal A], ER+/HER2+ or PR+/HER2+ 
[luminal B], ER−/PR−/HER2+ [HER2 overexpress-
ing or HER2+], and ER−/PR−/HER2−[TNBC])) com-
pared to controls (comparison group), and explanatory 
variable was alcohol consumption (light/moderate and 
heavy drinkers, considering abstainers as the reference 
group). All statistical analyses were performed using 
the Stata statistical software version10 (College Station, 
TX). All reported test significance levels (P values) were 
two-sided.
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